Revolution Medicines (RVMD) EPS (Weighted Average and Diluted) (2020 - 2026)
Revolution Medicines' quarterly EPS (Weighted Average and Diluted) came in at -$2.29 in Q1 2026, down 102.65% year-on-year from $86.26 in Q1 2025, and down 21.16% quarter-over-quarter from -$1.89 in Q4 2025.
Revolution Medicines has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$2.29 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 102.65% year-over-year to -$2.29; the trailing twelve-month figure through Mar 2026 stood at -$7.1 (down 77.06% YoY), and the FY2025 full-year result was -$5.95, down 66.2% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.29, down from -$1.89 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.61 in Q4 2022, with the low at -$2.29 in Q1 2026.
- Average EPS (Weighted Average and Diluted) over 5 years is -$1.1, with a median of -$0.94 recorded in 2024.
- Year-over-year, EPS (Weighted Average and Diluted) grew 15.28% in 2022 and plunged 102.65% in 2026.
- Tracing RVMD's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.61 in 2022, then slumped by 98.36% to -$1.21 in 2023, then advanced by 6.61% to -$1.13 in 2024, then slumped by 67.26% to -$1.89 in 2025, then fell by 21.16% to -$2.29 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.29 (Q1 2026), -$1.89 (Q4 2025), and -$1.61 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.29 |
| Dec 31, 2025 | -1.89 |
| Sep 30, 2025 | -1.61 |
| Jun 30, 2025 | -1.31 |
| Mar 31, 2025 | -1.13 |
| Dec 31, 2024 | -1.13 |
| Sep 30, 2024 | -0.94 |
| Jun 30, 2024 | -0.81 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -1.21 |
| Sep 30, 2023 | -0.99 |
| Jun 30, 2023 | -0.92 |
| Mar 31, 2023 | -0.72 |
| Dec 31, 2022 | -0.61 |
| Sep 30, 2022 | -0.87 |
| Jun 30, 2022 | -0.82 |
| Mar 31, 2022 | -0.78 |
| Dec 31, 2021 | -0.72 |
| Sep 30, 2021 | -0.72 |
| Jun 30, 2021 | -0.60 |
| Dec 31, 2020 | -0.62 |